HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

AORT

Artivion, Inc. (NYSE)

Healthcare — Medical Devices

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Strong Buy 1.3 / 5 8 analysts
$25.14
+$0.20 (+0.80%)
Target: $42.00 (67.1%)
Sign in to add AORT to a watchlist or set price alerts.

Price History

Fundamentals

Market Cap$1.14B
P/E Ratio (TTM)93.92
Forward P/E32.61
EPS (TTM)$0.25
Dividend Yield-
Profit Margin2.55%
Revenue Growth-
ROE-
Debt/Equity-
Recommendation Strong Buy 1.3
Analyst Target$42.00
Analysts8
Indexes NYSE

Technical Indicators

RSI (14)65.9
Beta1.26
SMA 20-
SMA 40-
52-Week High-
52-Week Low-
50-Day Avg-
200-Day Avg-
Avg Volume783.7K
Volume299.5K

Performance Analysis

BULLISH

AORT shows predominantly bullish signals based on its fundamentals and technicals.

+ RSI at 65.9 shows positive momentum.
- P/E of 93.9 is elevated — the market expects high growth or it may be overvalued.
+ Wall Street consensus is "Strong Buy" from 8 analysts.
+ Average analyst target of $42.00 implies 67.1% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 01, 2026 15:01 UTC

Back to Screener Export Report